Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease. / Ellegaard, Maria; Schwarz, Peter; Hansen, Ann Caroline; Faber, Jens; Vestergaard, Henrik.

In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 72, No. 7, 2012, p. 518-22.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ellegaard, M, Schwarz, P, Hansen, AC, Faber, J & Vestergaard, H 2012, 'Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 72, no. 7, pp. 518-22. https://doi.org/10.3109/00365513.2012.701321

APA

Ellegaard, M., Schwarz, P., Hansen, A. C., Faber, J., & Vestergaard, H. (2012). Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease. Scandinavian Journal of Clinical & Laboratory Investigation, 72(7), 518-22. https://doi.org/10.3109/00365513.2012.701321

Vancouver

Ellegaard M, Schwarz P, Hansen AC, Faber J, Vestergaard H. Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease. Scandinavian Journal of Clinical & Laboratory Investigation. 2012;72(7):518-22. https://doi.org/10.3109/00365513.2012.701321

Author

Ellegaard, Maria ; Schwarz, Peter ; Hansen, Ann Caroline ; Faber, Jens ; Vestergaard, Henrik. / Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease. In: Scandinavian Journal of Clinical & Laboratory Investigation. 2012 ; Vol. 72, No. 7. pp. 518-22.

Bibtex

@article{1ec821b1c2fe477c946ed4ed4a76fd11,
title = "Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease",
abstract = "Teriparatide (Parathyroid hormone (PTH) 1-34) has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral fractures when given intermittently. In contrast primary hyperparathyroidism (PHPT) is associated with increased bone loss. Moreover an increased occurrence of cardiovascular disease (CVD) is seen in PHPT patients. The N-terminal fragment of the pro-peptide of Brain Natriuretic peptide (NT-proBNP), a risk marker of CVD, has been shown to be elevated in PHPT patients, indicating that continuously high concentrations of PTH affect the heart. Therefore the aim of this study was to investigate whether teriparatide treatment is associated with changes in plasma NT-proBNP.",
author = "Maria Ellegaard and Peter Schwarz and Hansen, {Ann Caroline} and Jens Faber and Henrik Vestergaard",
year = "2012",
doi = "10.3109/00365513.2012.701321",
language = "English",
volume = "72",
pages = "518--22",
journal = "Scandinavian Journal of Clinical & Laboratory Investigation",
issn = "0036-5513",
publisher = "Taylor & Francis",
number = "7",

}

RIS

TY - JOUR

T1 - Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease

AU - Ellegaard, Maria

AU - Schwarz, Peter

AU - Hansen, Ann Caroline

AU - Faber, Jens

AU - Vestergaard, Henrik

PY - 2012

Y1 - 2012

N2 - Teriparatide (Parathyroid hormone (PTH) 1-34) has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral fractures when given intermittently. In contrast primary hyperparathyroidism (PHPT) is associated with increased bone loss. Moreover an increased occurrence of cardiovascular disease (CVD) is seen in PHPT patients. The N-terminal fragment of the pro-peptide of Brain Natriuretic peptide (NT-proBNP), a risk marker of CVD, has been shown to be elevated in PHPT patients, indicating that continuously high concentrations of PTH affect the heart. Therefore the aim of this study was to investigate whether teriparatide treatment is associated with changes in plasma NT-proBNP.

AB - Teriparatide (Parathyroid hormone (PTH) 1-34) has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral fractures when given intermittently. In contrast primary hyperparathyroidism (PHPT) is associated with increased bone loss. Moreover an increased occurrence of cardiovascular disease (CVD) is seen in PHPT patients. The N-terminal fragment of the pro-peptide of Brain Natriuretic peptide (NT-proBNP), a risk marker of CVD, has been shown to be elevated in PHPT patients, indicating that continuously high concentrations of PTH affect the heart. Therefore the aim of this study was to investigate whether teriparatide treatment is associated with changes in plasma NT-proBNP.

U2 - 10.3109/00365513.2012.701321

DO - 10.3109/00365513.2012.701321

M3 - Journal article

C2 - 22950623

VL - 72

SP - 518

EP - 522

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

SN - 0036-5513

IS - 7

ER -

ID: 48444484